throbber
Page 1
`
` UNITED STATES PATENT AND TRADEMARK OFFICE
` PATENT TRIAL AND APPEAL BOARD
`
` MYLAN PHARMACEUTICALS )
` INC. and AMNEAL )
` PHARMACEUTICALS LLC, ) Case Nos.
` )
` Petitioners, ) IPR2015-00643
` ) (8,232,250 B2)
` vs. ) IPR2015-00644
` ) (8,399,413 B2)
` YEDA RESEARCH AND ) IPR2015-00830
` DEVELOPMENT CO. LTD., ) (8,969,302 B2)
` )
` Patent Owner. )
` ------------------------- )
`
` February 2, 2016
` 8:15 a.m.
`
` Deposition of TJALF ZIEMSSEN, held at
` the offices of Perkins Coie LLP, 30
` Rockefeller Center, New York, New York, before
` Laurie A. Collins, a Registered Professional
` Reporter and Notary Public of the State of New
` York.
`
` Veritext Legal Solutions
` Mid-Atlantic Region
` 1250 Eye Street NW - Suite 1201
` Washington, D.C. 20005
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`1 2
`
`3
`
`4 5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`
`24
`
`25
`
`Page 1 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`Page 2
`
` A P P E A R A N C E S:
`
` PERKINS COIE LLP
`
` Attorneys for Petitioner Mylan
`
` 700 13th Street, N.W., Suite 600
`
` Washington, D.C. 20005-3960
`
` BY: SHANNON M. BLOODWORTH, ESQ.
`
` sbloodworth@perkinscoie.com
`
` BRANDON M. WHITE, ESQ.
`
` bwhite@perkinscoie.com
`
` - and -
`
` PERKINS COIE LLP
`
` One East Main Street, Suite 201
`
` Madison, Wisconsin 53703-5118
`
` BY: DAVID L. ANSTAETT, ESQ.
`
` danstaeet@perkinscoie.com
`
` - and -
`
` PERKINS COIE LLP
`
` 1888 Century Park East, Suite 1700
`
` Los Angeles, California 90067-1721
`
` BY: COURTNEY M. PROCHNOW, ESQ.
`
` cprochnow@perkinscoie.com
`
` - and -
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`1 2
`
`3 4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 2 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`Page 3
`
` A P P E A R A N C E S ( c o n t i n u e d ) :
`
` W I L S O N S O N S I N I G O O D R I C H & R O S A T I
`
` 1 2 2 3 5 E l C a m i n o R e a l , S u i t e 2 0 0
`
` S a n D i e g o , C a l i f o r n i a 9 2 1 3 0 - 3 0 0 2
`
` B Y : L O R E L E I P . W E S T I N , P H . D . , E S Q .
`
` l w e s t i n @ w s g r . c o m
`
` D U A N E M O R R I S L L P
`
` A t t o r n e y s f o r P e t i t i o n e r A m n e a l
`
` 1 0 0 H i g h S t r e e t , S u i t e 2 4 0 0
`
` B o s t o n , M a s s a c h u s e t t s 0 2 2 1 0 - 1 7 2 4
`
` B Y : C H R I S T O P H E R S . K R O O N , E S Q .
`
` c s k r o o n @ d u a n e m o r r i s . c o m
`
` G O O D W I N P R O C T E R L L P
`
` A t t o r n e y s f o r P a t e n t O w n e r
`
` 9 0 1 N e w Y o r k A v e n u e , N . W .
`
` W a s h i n g t o n , D . C . 2 0 0 0 1
`
` B Y : W I L L I A M G . J A M E S , E S Q .
`
` w j a m e s @ g o o d w i n p r o c t e r . c o m
`
` - a n d -
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`1 2
`
`3 4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`1 0
`
`1 1
`
`1 2
`
`1 3
`
`1 4
`
`1 5
`
`1 6
`
`1 7
`
`1 8
`
`1 9
`
`2 0
`
`2 1
`
`2 2
`
`2 3
`
`2 4
`
`2 5
`
`Page 3 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`Page 4
`
` A P P E A R A N C E S ( c o n t i n u e d ) :
`
` G O O D W I N P R O C T E R L L P
`
` T h e N e w Y o r k T i m e s B u i l d i n g
`
` 6 2 0 E i g h t h A v e n u e
`
` N e w Y o r k , N e w Y o r k 1 0 0 1 8 - 1 4 0 5
`
` B Y : D A N I E L P . M A R G O L I S , P H . D . , E S Q .
`
` d m a r g o l i s @ g o o d w i n p r o c t e r . c o m
`
` - a n d -
`
` G O O D W I N P R O C T E R L L P
`
` E x c h a n g e P l a c e
`
` 5 3 S t a t e S t r e e t
`
` B o s t o n , M a s s a c h u s e t t s 0 2 1 0 9
`
` B Y : J O H N T . B E N N E T T , E S Q .
`
` j b e n n e t t @ g o o d w i n p r o c t e r . c o m
`
` A L S O P R E S E N T :
`
` M A T T H E W G R E I N E R T , E S Q . ( M y l a n )
`
` L O R I W O L F E , E S Q . ( T e v a )
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`1 2
`
`3 4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`1 0
`
`1 1
`
`1 2
`
`1 3
`
`1 4
`
`1 5
`
`1 6
`
`1 7
`
`1 8
`
`1 9
`
`2 0
`
`2 1
`
`2 2
`
`2 3
`
`2 4
`
`2 5
`
`Page 4 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`Page 5
`
` T J A L F Z I E M S S E N ,
`
` called as a witness, having been duly sworn
`
` by the notary public, was examined and
`
` testified as follows:
`
` EXAMINATION BY
`
` MS. BLOODWORTH:
`
` Q. Good morning, Dr. Ziemssen. My name is
`
` Shannon Bloodworth. I'm an attorney for the
`
` petitioners, Mylan, and I work with the firm
`
` Perkins Coie.
`
` Sir, if I say Dr. Ziemssen, am I close
`
` in pronouncing your name correctly?
`
` A. It's fine, yes.
`
` Q. If I mess up, just let me know, please.
`
` And can you please state and spell your
`
` name for the record?
`
` A. T-H-A-L-F, Z-I-E-M-S-S-E-N [sic].
`
` Q. And have you ever had your deposition
`
` taken before?
`
` A. No, it's my first deposition.
`
` Q. So just to go over a little bit of the
`
` ground rules, then, I'll ask some questions.
`
` You'll have the opportunity to answer. If you
`
` don't understand any of the questions, please let
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`1 2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 5 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 6
`
` Ziemssen
`
` me know, I'll try to clarify it or make it -- or
`
` ask a different question. However, you are
`
` supposed to be responsive to the questions that I
`
` ask.
`
` If at any time your counsel has
`
` questions, he has the opportunity at the end of
`
` the deposition after my questions to ask you
`
` questions.
`
` Obviously I have a cold today, so if
`
` you cannot hear me, please let me know. I will
`
` speak up. And if you ever need a break, feel free
`
` to take one. Just let me know. And we'll finish
`
` out the questions, and we'll go ahead and take a
`
` break.
`
` A. That's my understanding.
`
` Q. And it's my understanding we should try
`
` to get finished by 5 o'clock today because you
`
` have a flight, so we'll endeavor to do that.
`
` Aside from this matter here today, have
`
` you ever been retained by Yeda as an expert?
`
` A. What do you mean with this?
`
` Q. Have you ever been asked to provide any
`
` expert testimony in the form of a declaration or
`
` an affidavit, for instance?
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 6 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 7
`
` Ziemssen
`
` A. You mean as declaration like this
`
` declaration have been?
`
` Q. Yes.
`
` A. No, it's my first declaration.
`
` Q. Okay.
`
` And aside from your interactions with
`
` Teva or Yeda for this matter, have you ever been
`
` retained by Yeda for any of your services, for any
`
` services?
`
` A. What do you mean with "retained"?
`
` Q. Have you ever had an agreement under
`
` which you performed work for Yeda?
`
` A. What kind of work do you mean?
`
` Q. Any kind of work on, say, for example,
`
` a clinical trial or other work that you would
`
` perform under a contractual obligation with Yeda.
`
` A. So I had a contract on speaking
`
` activities with Teva, not with Yeda.
`
` Q. And when did you enter into that
`
` agreement with Teva?
`
` A. Pardon?
`
` Q. When did you enter into that agreement
`
` with Teva?
`
` A. I cannot recall when it started.
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 7 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 8
`
` Ziemssen
`
` Q. Do you recall approximately when it
`
` started? Was it before or after the year 2000?
`
` A. It was after 2000, yes.
`
` Q. Was it around two thousand -- do you
`
` recall if it was around 2010?
`
` A. I think it was earlier than 2010.
`
` Q. And what type of speaking activities
`
` did you perform?
`
` A. What do you mean with "types of
`
` activities"?
`
` Q. You said that you had a contract on
`
` speaking activities. What did you mean by that?
`
` What did that entail?
`
` A. In Germany it's the case that you are
`
` asked to give a speech, and then you get a
`
` separate contract. So you don't have a contract
`
` which is including a certain quantity of talks
`
` or -- you're asked to give a talk, and then you
`
` get a contract which has to be approved by your
`
` administration.
`
` Q. Is that contract still in good
`
` standing? Are you still under that contractual
`
` obligation with Teva?
`
` A. No. As I have stated, if I have to
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 8 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 9
`
` Ziemssen
`
` give a speech, I get a separate contract. So I
`
` have no contract which is ongoing. For each
`
` activity I get a separate contract.
`
` Q. Okay. Thank you.
`
` Approximately how many contracts have
`
` you had? Do you recall?
`
` A. I cannot recall.
`
` Q. Was it more than ten?
`
` A. Yes, I think so.
`
` Q. More than 20?
`
` A. Yes, I think so.
`
` Q. More than 50, 5-0?
`
` A. I cannot recall.
`
` Q. Okay. So to the best of your
`
` recollection you've had approximately more than 20
`
` speaking engagements for Teva?
`
` A. That is fine, yes.
`
` Q. Were those all related to Copaxone?
`
` A. No.
`
` Q. Were some of them?
`
` A. Yes, some of them.
`
` Q. Were the others related to a different
`
` MS drug?
`
` A. Partially, yes.
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 9 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 10
`
` Ziemssen
`
` Q. Laquinimod?
`
` A. Yes, one of them, yes.
`
` Q. Do you recall any others?
`
` A. No, I cannot recall.
`
` Q. Doctor, I'm going to hand you what was
`
` marked as Yeda Exhibit Number 2135. It's entitled
`
` the declaration of Tjalf Ziemssen, M.D., Ph.D., in
`
` support of patent owner Yeda's response to
`
` petition for inter partes review, and it was
`
` submitted in Case Number IPR2015-00643.
`
` And, sir, if I can ask you to keep that
`
` one handy. We're going to mark your other two
`
` declarations, but we're going to refer primarily
`
` to the '250 in the 643 case.
`
` A. Okay. Good.
`
` Q. Let's also mark Yeda Exhibit Number
`
` 2135, and it's the same title for the declaration
`
` submitted in support of Case Number IPR2015-00644
`
` related to patent number 8,399,413. And also
`
` marked as Yeda Exhibit Number 2135 with the same
`
` title is your declaration submitted in support of
`
` IPR2015-00830 for U.S. patent number 8,969,302.
`
` And as I mentioned, sir, today I'm
`
` going to be referring primarily to the first
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 10 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 11
`
` Ziemssen
`
` document that I handed you, which is related to
`
` the '250 patent. And by that, that's the
`
` abbreviation for which we refer to U.S. patent
`
` numbers. Typically we use the last three digits.
`
` Is that familiar to you?
`
` A. I'm familiar with it, yes.
`
` Q. So when I refer to the '250 patent,
`
` you'll understand I'm referring to the one in this
`
` declaration?
`
` A. I understand, yes.
`
` Q. Now, if you ever need to answer any of
`
` my questions -- in my opinion they're pretty
`
` similar, but if you ever need to look at any of
`
` the other declarations to answer any questions,
`
` please feel free to do so.
`
` A. I will do so.
`
` Q. Okay. In the '250 patent in paragraph
`
` 20 on page 6, you mentioned --
`
` MR. JAMES: Do you mean his
`
` declaration? You said '250 patent.
`
` MS. BLOODWORTH: Did I?
`
` MR. JAMES: Yes.
`
` Q. I do mean your declaration. I don't
`
` think you wrote any of the '250 patent; correct?
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 11 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 12
`
` Ziemssen
`
` A. I don't think so.
`
` Q. Let's just get that clear for the
`
` record; right? Definitely your '250 declaration.
`
` You state that a copy of my current
`
` curriculum vitae is attached hereto as Exhibit
`
` 2131. So let's go ahead and get that in the
`
` record. And we'll also at the same time do 2132.
`
` I'm going to hand you what was marked
`
` Yeda Exhibit Number 2131. And again, this is in
`
` support of the '250 case declaration. It's two
`
` pages. I'm also handing you what was marked as
`
` Yeda Exhibit Number 2132, which is also two pages.
`
` Turning to Exhibit 2131, is this a
`
` current copy of your CV?
`
` A. Yes, it is.
`
` Q. Do you have a full CV?
`
` A. What do you mean with "full CV"?
`
` Q. A CV that lists all of your
`
` publications and speaking engagements and
`
` abstracts, for example.
`
` A. No, I haven't.
`
` Q. And what I also handed you marked or
`
` referred to as Exhibit 2132 in your declaration,
`
` and in paragraph 16 of your declaration, you state
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 12 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 13
`
` Ziemssen
`
` that Exhibit 2132 is a, quote, full listing of the
`
` clinical trials in which you participated as an
`
` investigator. Do you see that?
`
` A. Yes. But it's stated -- it's stated
`
` that it's the clinical trial over the past five
`
` years. So it's not a full list; it's the past
`
` five years.
`
` Q. Okay. So in your report you don't
`
` qualify the last five years, but that is what 2132
`
` is is the last five years?
`
` A. (Nods head.)
`
` Q. Why did you limit it to the last five
`
` years?
`
` A. That is German standard.
`
` Q. And do you have any corrections that
`
` you would like to make to either of these two
`
` exhibits or any updates that you would like to
`
` add?
`
` A. No, I have not.
`
` Q. Is Exhibit 2132 something that you
`
` maintain in your ordinary course or did you
`
` prepare this specifically for this litigation?
`
` A. What do you mean exactly with this?
`
` Q. Did you prepare this listing for this
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 13 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 14
`
` Ziemssen
`
` declaration or is this something you keep in your
`
` files?
`
` A. I keep it in my files.
`
` Q. And in the last I guess five years, I
`
` counted that there are approximately 31 trials
`
` listed on Exhibit 2132, and two of those relate to
`
` glatiramer acetate; correct?
`
` A. Yes, that is right.
`
` Q. And the two that I saw were the GALA
`
` trial in the middle of the first page and the
`
` FORTE trial listed as the first entry? Are those
`
` two the same you found?
`
` A. That is right, FORTE and GALA.
`
` Q. The FORTE trial was more than four
`
` years ago; correct?
`
` A. I cannot recall exactly.
`
` Q. And if you turn to your declaration in
`
` paragraph 16, it shows that you list the FORTE
`
` trial, a trial called COPTIMIZE, and a trial
`
` called QualiCOP.
`
` Why is the COPTIMIZE trial not listed
`
` on Exhibit 2132?
`
` A. Because both trials, COPTIMIZE and
`
` QualiCOP trials, are noninterventional trials,
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 14 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 15
`
` Ziemssen
`
` observational trials. This is only a list of the
`
` clinical trials.
`
` Q. So you participate in observational
`
` trials too; correct?
`
` A. That's right.
`
` Q. What is the purpose of an observational
`
` trial?
`
` A. You cannot say it in general what is
`
` the purpose of observational trials. It depends
`
` on the trial.
`
` Q. But certainly there is a purpose to it;
`
` correct?
`
` A. Pardon?
`
` Q. There is a purpose to it?
`
` MR. JAMES: Objection to the form.
`
` A. What do you mean with this?
`
` Q. Well, observational trials provide some
`
` meaning to the art. There's a purpose for
`
` performing the trial; correct?
`
` A. I do not understand the wording
`
` "purpose."
`
` Q. Do they have an objective?
`
` A. Observational trials document clinical
`
` parameters which are standard of care.
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 15 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 16
`
` Ziemssen
`
` Q. Okay. And why was the COPTIMIZE
`
` observational trial conducted?
`
` A. COPTIMIZE trial was conducted to
`
` document clinical parameters switching from
`
` interferons to glatiramer acetate.
`
` Q. Why would you want to document the
`
` clinical parameters?
`
` A. We wanted to document clinical
`
` parameters to compare patients switching from
`
` interferon because of lack of efficacy versus
`
` tolerability reasons.
`
` Q. I think this is going to be
`
` Petitioners' Exhibit Number 1079. I'm going to
`
` hand you a document that was published in the
`
` Journal of Neurology in 2014, and it's called a
`
` two-year observational study of patients with
`
` relapsing-remitting multiple sclerosis converting
`
` to glatiramer acetate from other disease-modifying
`
` therapies: the COPTIMIZE trial. And it looks
`
` like it runs from pages 2101 through 2111.
`
` (Discussion off the record.)
`
` Q. Is this a paper that you authored that
`
` you're the primary author for relating to the
`
` COPTIMIZE trial?
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 16 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 17
`
` Ziemssen
`
` A. I was the primary author of the paper,
`
` yes.
`
` Q. How many papers did you author -- how
`
` many papers were you the author on relating to the
`
` COPTIMIZE trial?
`
` A. We have two full papers on the
`
` COPTIMIZE trial.
`
` Q. Two. Okay.
`
` And if you turn to the second page,
`
` 2102, it lists the study design under "methods."
`
` And it states that COPTIMIZE was a two-year
`
` international, multicenter, prospective,
`
` noninterventional, longitudinal, and observational
`
` study conducted in 148 study centers across 19
`
` countries.
`
` Who sponsored this study?
`
` A. Teva sponsored this trial.
`
` Q. And were you the lead investigator on
`
` this trial? Were you the principal investigator
`
` on the trial?
`
` A. I was the principal investigator of
`
` this trial, yes.
`
` Q. Why did Teva want a two-year
`
` international, multicenter, prospective,
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 17 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 18
`
` Ziemssen
`
` noninterventional, longitudinal, and observational
`
` study to be conducted?
`
` MR. JAMES: Objection to the form.
`
` A. Pardon, I haven't got the question.
`
` Q. Why did Teva want this study to be
`
` performed?
`
` MR. JAMES: Objection to the form.
`
` A. I don't know.
`
` Q. Do you have an agreement with Teva for
`
` this study?
`
` A. I had an agreement as principal
`
` investigator of this trial.
`
` Q. And Teva paid for this trial to be
`
` conducted; correct?
`
` A. It is stated at the end of the
`
` manuscript that this study was supported by Teva
`
` Pharmaceuticals Industries.
`
` Q. And what does "supported by" mean?
`
` A. I don't know what you mean concretely.
`
` Q. Did they provide the samples for the
`
` studies and the product to be administered?
`
` A. No, they haven't.
`
` Q. Did they provide the glatiramer acetate
`
` to be administered?
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 18 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 19
`
` Ziemssen
`
` A. No, they haven't.
`
` Q. Who paid for that? Did the patients
`
` pay for that?
`
` A. Depending on the country, patients or
`
` health insurances.
`
` Q. So when you wrote the study was
`
` sponsored by Teva, what did that mean?
`
` MR. JAMES: Objection.
`
` A. So it's stated the study was supported
`
` by Teva Pharmaceuticals.
`
` Q. What kind of support did Teva provide?
`
` A. I cannot recall.
`
` Q. Clinical trials aren't cheap, though;
`
` right?
`
` MR. JAMES: Objection to the form.
`
` A. I don't know.
`
` Q. How much did you spend on this study,
`
` your group? How much did you invest, personal
`
` time, resources?
`
` A. I don't know.
`
` Q. Was it free? Did you perform the study
`
` for free?
`
` A. No, as stated, I had a contract
`
` agreement with Teva.
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 19 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 20
`
` Ziemssen
`
` Q. And in this study you say on page 2109,
`
` quote, Despite study limitations, our
`
` observations -- do you see where I am, 2109, under
`
` Table 5 in the right-hand column? You write,
`
` Despite study limitations, our observations
`
` corroborate the results of previous studies in
`
` which improved treatment response (i.e., reduced
`
` ARR, delayed disease progression) was observed in
`
` patients who converted from one DMT to another.
`
` Sub footnotes.
`
` Do you see that?
`
` A. That's stated in the paper, yes.
`
` Q. And that is you stating the
`
` observations from the COPTIMIZE trial for the
`
` public's review; correct?
`
` A. I don't understand your question.
`
` Q. This article you put out in the public
`
` literature; correct? It's in the Journal of
`
` Neurology?
`
` A. This manuscript was written by me, yes.
`
` Q. Yes. Published in the Journal of
`
` Neurology; yes?
`
` A. It was published in the Journal of
`
` Neurology.
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 20 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 21
`
` Ziemssen
`
` Q. Okay. And you're stating your
`
` observations and what they corroborate in your
`
` mind; correct?
`
` A. That's stated in the text.
`
` Q. And you go on and you state, Our
`
` findings also emphasize the importance of changing
`
` a therapeutic regimen to improve patients'
`
` well-being (i.e., QOL -- stands for quality of
`
` life?
`
` A. That's fine.
`
` Q. Okay. The quote continues, depression,
`
` fatigue) and control disease progression while
`
` overcoming treatment barriers (i.e., intolerable
`
` AEs) that could compromise compliance among
`
` patients responding suboptimally to their current
`
` regimen and result in further disease progression.
`
` Do you see that?
`
` A. That's stated, yes.
`
` Q. So you're emphasizing in this published
`
` article the importance of changing from one regime
`
` to another; correct?
`
` A. I don't agree with the statement.
`
` Q. Our findings also emphasize the
`
` importance of changing a therapeutic regime to
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 21 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 22
`
` Ziemssen
`
` improve patients' well-being and to control
`
` disease progression.
`
` A. That's stated in my text.
`
` Q. Did you expect persons of skill in the
`
` art reading this to follow or to be guided by your
`
` observations?
`
` MR. JAMES: Objection to the form.
`
` A. What do you mean with this question?
`
` Q. Why did you write this?
`
` A. To draw conclusions from our
`
` observation published in the manuscript.
`
` Q. And people would want to hear those
`
` conclusions -- right? -- two years' worth of work?
`
` MR. JAMES: Objection to the form.
`
` A. I don't know what you mean.
`
` Q. Well, did you think this article would
`
` not be read?
`
` A. You author an article to publish your
`
` data and to comment on this data.
`
` Q. For use by others in your field;
`
` correct?
`
` A. I don't know exactly who's reading the
`
` Journal of Neurology.
`
` Q. Okay. But if somebody is reading the
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 22 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 23
`
` Ziemssen
`
` Journal of Neurology, would they suspect that your
`
` observations are unfounded?
`
` MR. JAMES: Objection to the form.
`
` Q. Okay. Rephrase.
`
` Would they discard your observations
`
` provided in this study?
`
` MR. JAMES: Objection to the form.
`
` A. What do you mean with "discard"?
`
` Q. You wrote this for a purpose; right?
`
` A. To comment on my results, yes.
`
` Q. Did you expect people to read this and
`
` be informed by it?
`
` A. I published this paper to present my
`
` results and to comment on the results.
`
` Q. Right. But if nobody was going to read
`
` them, you wouldn't have a reason to comment on
`
` them and publish them; right?
`
` A. I don't know what you mean.
`
` Q. Did you expect doctors to read this
`
` article and convert patients to Copaxone to be a
`
` first-line treatment for MS?
`
` A. I don't agree with the statement.
`
` Q. Did you think it would provide them
`
` helpful information if they were considering
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 23 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 24
`
` Ziemssen
`
` switching their patients to Copaxone?
`
` A. Could you specify your question,
`
` please?
`
` Q. Let's read. You say you recommend or
`
` you state patients whose disease is progressing on
`
` their current DMT need to be converted in a timely
`
` manner, right on the paragraph we were on
`
` previously. It's the first sentence of the second
`
` full paragraph.
`
` A. Uh-huh.
`
` Q. So I'll state you write, Patients whose
`
` disease is progressing on their current DMT need
`
` to be converted in a timely manner.
`
` A. Yes, that is stated in the text.
`
` Q. Then you state, Future clinical trial
`
` design should include patients converting from one
`
` DMT to another as a study arm. These trials could
`
` contribute to the development of consensus
`
` statements, treatment algorithms, and clinical
`
` parameters for changing treatment. This is
`
` important, as converting treatments is not always
`
` necessary and is associated with significant
`
` health care costs.
`
` A. That is stated in the manuscript.
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`Page 24 of 295
`
`YEDA EXHIBIT NO. 2147
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 25
`
` Ziemssen
`
` Q. So your recommendation is that
`
` following these observations you've published in
`
` the Journal of Neurology there should be another
`
` trial that should follow and you lay it out. You
`
` say it could contribute to the development of
`
` consensus statements and other things and you
`
` recommend that the trial design should include
`
` patients converting from one DMT to another as a
`
` study arm.
`
` MR. JAMES: Objection to the form.
`
` Q. Is that your recommendation, that
`
` future clinical trial designs should include
`
` patients converting from one DMT to another as a
`
` study arm?
`
` A. That's stated in my text, yes.
`
` Q. So you had every expectation that
`
` someone reading this would think to perform a
`
` clinical trial that is designed to include
`
` patients converting from one DMT to another as a
`
` study arm?
`
` MR. JAMES: Objection to the form.
`
` A. I stated the future clinical trials
`
` should include patients conv

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket